61 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
7 May 24
Cogent Biosciences Reports First Quarter 2024 Financial Results
8:19am
at the American Society of Clinical Oncology (ASCO) annual meeting taking place May 31-June 4, 2024. PEAK is the Company’s ongoing Phase 3 trial evaluating
8-K
EX-99.1
ry9 3l47uv
26 Feb 24
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
8:30am
8-K
2bupbp ejrw9pj2d
11 Dec 23
Other Events
8:04am
8-K
EX-99.1
tip1zk0 mmrddv
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
424B5
6zcnyf7dg4hqko xat4h
8 Jun 23
Prospectus supplement for primary offering
4:01pm
424B5
xhu6xbqmqilt9tqdnyi5
6 Jun 23
Prospectus supplement for primary offering
5:22pm
8-K
l7fasar ai6cn2
6 Jun 23
Other Events
4:03pm
8-K
EX-99.1
h64tip584 r4
9 May 23
Cogent Biosciences Reports Recent Business Highlights and First Quarter
8:13am
8-K
EX-99.2
sfcqcursbi7by5n6hjey
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
oxlauskdrmim375
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
k0gnwik7n2 u3uhh
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am